AMD Central.org provides access to resources for patients and caregivers in one location The American Macular Degeneration Foundation, BrightFocus Foundation, MD Support, Prevent Blindness and The SupportSight Foundation have launched AMD Central, an online resource that curates trusted information and tools from leading advocacy organizations to support the age-related macular degeneration (AMD) patient and caregiver community. [Read More]
Category: Latest News
Don’t Blame Everything On Your Macula
So your sight is slowly diminishing, and your ophthalmologist told you that nothing could be done. They said that the cells in the very center of your retina (the macula) are degenerating, and gradual loss of clear eyesight is to be expected. Still, they want to see you at least once a year unless you [Read More]
Latest statistics on prevalence of blindness and low vision worldwide
The Vision Loss Expert Group (VLEG) has published new findings about four areas of interest to the blind and low vision community. The report provides timely updates on acuity measurement standards, prevalence of global cases, and prevalence of types of blindness and vision impairment. For those who are interested in statistics, here are summaries of [Read More]
Newest Sustained-Release Anti-VEGF Drug in Trials
EyePoint Pharmaceuticals, Inc. announced on January 28, 2021 that the first patient has been dosed in their Phase 1 clinical trial of EYP-1901. EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration (wAMD). It is the newest of several sustained delivery drugs under study, this one promising to extend [Read More]
Faricimab for wet AMD effective at 16-week intervals
Genentech has announced positive topline results from its Phase III studies, TENAYA and LUCERNE, evaluating its new drug faricimab, for people with wet (neovascular) age-related macular degeneration (nAMD). Both studies have shown that people receiving faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes as effective as those receiving [Read More]